Eli Lilly reported Q3 2026 Mounjaro revenue of $10.7 billion, up 65% year-over-year, exceeding consensus estimates near $10.1 billion as worldwide volume rose 53% and offset a 15% decline in realized prices. U.S. sales grew 41% to $5.0 billion on sustained demand, while international revenue surged 93% to $5.7 billion, supported by expanded access including China's NRDL listing that boosted volume despite lower prices. The tirzepatide franchise (Mounjaro and Zepbound) drove the bulk of Lilly's $24.4 billion total revenue, prompting the company to raise full-year 2026 revenue guidance to $91–92 billion. Traders monitoring resolution thresholds will focus on these volume trends versus ongoing pricing dynamics and any last-minute adjustments to rebate estimates ahead of final figures.
基於Polymarket數據的AI實驗性摘要。這不是交易建議,也不影響該市場的結算方式。 · 更新於1H6H1D7D30DALL
View resolved

警惕外部連結哦。
警惕外部連結哦。
Frequently Asked Questions